Skip to content
Peptide research

Vesugen

Category
Bioregulators
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

A tripeptide bioregulator (lysine-glutamate-aspartate) marketed for vascular and endothelial health and slower biological aging. Evidence is mostly mechanistic and animal-based, with rejuvenation and blood-flow claims resting on preliminary laboratory findings and small human studies. Human safety data is very limited, independent validation is lacking, and prooxidant activity has been seen. Available products are unregulated, and Vesugen is not an approved drug in the US.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Vesugen (Lys-Glu-Asp, or KED) is a synthetic 3-amino-acid peptide from the Khavinson bioregulator family, designed to support blood vessel health. Developed at the St. Petersburg Institute of Bioregulation and Gerontology, it was synthesized to mimic the protective components found in natural peptide extracts from cattle blood vessels. Vesugen targets the endothelial cells that line your blood vessels to promote healthy vascular function.

How it works in the body

A tripeptide bioregulator (Lys-Glu-Asp) that targets vascular endothelial cells. It penetrates these cells and interacts with regulatory DNA sequences to normalize the expression of genes involved in endothelial nitric oxide synthesis, vascular tone regulation, and protection against atherosclerotic damage.

Research overview

Vesugen is proposed to work by entering vascular cells and influencing gene expression at the DNA level, targeting genes involved in blood vessel tone, cell-to-cell communication, and vessel wall maintenance. Key targets include endothelin-1 (involved in vessel constriction), gap junction proteins (cell communication), SIRT1 (a longevity-associated protein), and nitric oxide synthase (which controls blood flow). Clinical studies in elderly patients with peripheral vascular disease showed improved blood flow parameters, and it slowed biological aging markers more effectively than a comparison neuropeptide. About 30 publications exist, but nearly all come from Russian research groups. The largest clinical study involved only 41 patients, no randomized placebo-controlled trials have been conducted, and no independent Western replication has been published.

Who researches Vesugen?

Commonly researched by

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(7)

Rated by level of concern

  • Very limited human safety data

    High

    PMID 26390612 (the sole indexed human study); ClinicalTrials.gov search returns no Vesugen/KED studies

  • Lack of independent safety validation

    High

    Europe PMC/PubMed author analysis of all indexed Vesugen records (each traces to the Khavinson group)

  • Prooxidant activity observed

    Moderate

    PMID 26390612 (prooxidant activity by chemiluminescence); PMID 18546826 (peptides restricted lipid peroxidation of human lipoproteins without direct antioxidant activity)

  • Research-grade product quality concerns

    Moderate

    FDA - no approved application or DESI listing for Vesugen/Lys-Glu-Asp

  • Mild gastrointestinal effects

    Low

    No AE data in PMID 26390612; oral KED route confirmed described in PMID 34173097 (KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease)

  • Injection site reactions (injectable form)

    Low

    Class-based inference; no Vesugen injection safety publication identified

  • Hematopoietic suppression signal

    Moderate

    PMID 26390612 — 'significant inhibition of hemopoiesis' via 'decrease of markers CD34+ positive hematopoietic polypotent cells.'

Interaction summary(7)

Rated by direction with this peptide

  • Myelosuppressive agents (cytotoxic chemotherapy, methotrexate, azathioprine)

    CautionModerate

    The one human study reported reduced circulating CD34+ hematopoietic stem cells, so co-use with drugs that already suppress marrow function is the most substantiated concern and argues for monitoring blood counts.

    PMID 26390612 (CD34+ decrease)

  • Antihypertensive drugs (ACE inhibitors, ARBs, calcium channel blockers)

    CautionTheoretical

    Vesugen has a documented vasoprotective effect via Ki-67 epigenetic regulation of endothelial cell proliferation, so a chronic vascular effect that adds to blood-pressure-lowering therapy is conceivable in principle; however, no eNOS/nitric-oxide mechanism, interaction study, or human hemodynamic data exists, so this is speculative.

    Vasoprotective/endothelial mechanism per PMID 25051766; no interaction or hemodynamic study published

  • Anticoagulants and antiplatelet agents (warfarin, DOACs, aspirin, clopidogrel)

    CautionTheoretical

    Endothelial modulation could in theory shift the hemostatic balance, and the CD34+ finding raises a nonspecific hematologic flag; there are no coagulation, platelet-function, or bleeding data for Vesugen.

    Mechanistic inference plus hematologic signal in PMID 26390612

  • Antioxidant supplements and therapies (vitamin C, vitamin E, NAC)

    NeutralLow

    Vesugen showed prooxidant activity on chemiluminescence and is explicitly described as a non-antioxidant-type geroprotector, so pairing with antioxidants may blunt or confound its reported effects rather than cause harm; the interaction is about efficacy/confounding, not a safety hazard.

    PMID 26390612; PMID 18546826

  • Statins and other lipid-lowering therapy

    SynergisticTheoretical

    Both target endothelial protection and atherogenesis, and Vesugen has a documented endothelial Ki-67 effect that overlaps the anti-atherosclerotic short-peptide concept, but no combination study exists in animals or humans.

    Vesugen endothelial effect PMID 25051766; anti-atherosclerotic short-peptide concept PMID 25408528 (tests peptides T-38/RR-1, not Vesugen)

  • Other Khavinson short peptides (Pinealon, Epitalon, Cortagen)

    NeutralTheoretical

    Co-administration of Vesugen and Pinealon was used in the single human study without any reported interaction, and the peptides are described as tissue-specific, so cross-interference appears unlikely but is untested.

    PMID 26390612 (Vesugen+Pinealon co-administration)

  • Peptide transporter (PEPT1/PEPT2, LAT) substrates

    CautionTheoretical

    Ultrashort peptides including KED are proposed to enter cells via POT and LAT carriers, creating a theoretical competition point with drugs that use the same transporters (e.g. beta-lactams, valacyclovir, levodopa), with no in vivo evidence of clinically meaningful competition.

    PMID 35887081 (Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers, Int J Mol Sci 2022)

Known risks(7)

  • Very limited human safety data

    High

    Published clinical reports are small; the number of unique Vesugen-treated patients across them has not been established. No long-term safety data exists beyond 6 months. No dose-escalation safety studies have been conducted. The safety profile is extrapolated primarily from the general tolerability of short peptides and the absence of reported serious adverse events in small Russian studies.

  • Lack of independent safety validation

    High

    All clinical data originates from a single research ecosystem (Khavinson / SPIBG). No independent Western research groups have evaluated Vesugen safety in humans. The absence of reported adverse events in small, uncontrolled studies does not constitute robust safety evidence.

  • Prooxidant activity observed

    Moderate

    The Meshchaninov et al. 2015 study (PMID 26390612) noted prooxidant activity through chemiluminescence measurement during Vesugen treatment. This is the opposite of an antioxidant effect and could theoretically exacerbate oxidative stress in vulnerable patients, particularly those with existing cardiovascular disease or inflammatory conditions.

  • Research-grade product quality concerns

    Moderate

    Unregulated Vesugen products sold online lack pharmaceutical-grade quality controls, GMP certification, and rigorous purity verification. Contamination with synthesis byproducts, incomplete sequences, or endotoxins is possible. Injectable use of research-grade peptides carries additional infection and sterility risks.

  • Mild gastrointestinal effects

    Low

    Mild nausea has been reported in less than 5% of users in clinical observations. Occasional headaches have been noted in less than 3% of cases. These effects are generally self-limiting.

  • Injection site reactions (injectable form)

    Low

    When administered by injection rather than orally, minor skin irritation, redness, or itching at the injection site has been reported anecdotally. No systematic assessment of injection site reactions has been published.

  • Hematopoietic suppression signal

    Moderate

    The Meshchaninov et al. 2015 study (PMID 26390612) reported a decrease in CD34+ positive hematopoietic polypotent cells in blood, indicating significant inhibition of hemopoiesis. This finding warrants caution, particularly in patients with anemia or bone marrow disorders, though it has not been replicated in subsequent studies.

Drug interactions(6)

  • Antihypertensive agents (ACE inhibitors, ARBs, calcium channel blockers)

    Theoretical additive blood pressure lowering. Vesugen's proposed mechanism includes normalization of eNOS expression and improvement of vascular tone. If these effects are clinically meaningful, combined use with antihypertensives could produce excessive hypotension. Blood pressure should be monitored more frequently during Vesugen courses. No formal interaction studies exist.

  • Anticoagulants and antiplatelet agents (warfarin, heparin, aspirin, clopidogrel)

    Theoretical concern. Vesugen modulates endothelial function and vascular homeostasis. Changes in endothelial cell behavior could theoretically alter the balance between pro- and anti-thrombotic factors at the vessel wall. No clinical interaction data exists, but caution is warranted in patients on anticoagulant therapy.

  • Statins (HMG-CoA reductase inhibitors)

    No documented interactions. Both statins and Vesugen target vascular health through different mechanisms (cholesterol synthesis vs. epigenetic gene regulation). Theoretical synergy is possible but untested. Drug interactions are untested with heart medications — proceed cautiously.

  • Vasodilators (nitrates, sildenafil, tadalafil)

    Theoretical additive vasodilatory effect. The clinical study on vasculogenic erectile dysfunction (PMID 25051774) used Vesugen in a patient population likely also using PDE5 inhibitors for ED. Combined eNOS upregulation (Vesugen) with NO-cGMP pathway potentiation (PDE5 inhibitors/nitrates) could theoretically cause excessive vasodilation and hypotension.

  • Other peptide therapies and bioregulators

    The clinical study by Meshchaninov et al. (PMID 26390612) compared Vesugen with Pinealon, but did not combine them. No data exists on interactions between Vesugen and other Khavinson peptides (Epithalon, Thymalin, etc.) or mainstream peptide therapies (GLP-1 agonists, BPC-157). Combined bioregulator protocols are common in Khavinson practice but pharmacologically uncharacterized.

  • Immunosuppressants

    Vesugen enhanced proliferation of immune cells in pineal gland tissue (PMID 22803057) and modulates immune markers (CD5, CD68). Theoretical interference with immunosuppressive drug efficacy is possible. No clinical data available.

Research & benefits

Evidence base

Evidence Level
Limited Evidence
Total Studies
30
Human Studies
3

Human evidence for Vesugen is extremely limited, consisting primarily of small Russian clinical studies without randomization, blinding, or placebo controls. Two vascular reports each describe 41 patients. PMID 28976154 concerns lower-limb ischemia; despite its title, PMID 25051774 describes vasculogenic erectile dysfunction and penile blood flow. Participant overlap is unknown. The geroprophylaxis study (PMID 26390612) enrolled 32 patients and measured biological aging markers. These studies are suggestive but methodologically weak by Western standards. The majority of Vesugen evidence (~85%) comes from in vitro cell culture and animal models. No independent Western research groups have replicated the clinical findings.

Researched for(6)

Rated by confidence in the evidence

  • Vascular endothelial cell rejuvenation and Ki-67 restoration

    Low

    Restored a proliferation marker in cultured endothelial cells; not tested in vivo or in humans.

    PMID 25051766 (Adv Gerontol 2014, Khavinson et al.) — Vesugen stimulated Ki-67 and interacted with the MKI67 promoter in endothelial cultures. Class-level context only: PMID 25408528 (anti-atherosclerotic short peptides), which does not test Vesugen (studies peptides T-38 and RR-1) and does not establish a Vesugen-specific mechanism.

  • Improved peripheral vascular blood flow in elderly patients

    Speculative

    A small before-and-after study reports improved lower-limb blood-flow measures in 41 patients; causal benefit remains uncertain.

    PMID 28976154: primary report of lower-limb blood-flow measurements in 41 patients.

  • Neuroimmunoendocrine cell proliferation and anti-apoptotic effects

    Low

    Shown only in one lab's rat tissue culture study, not confirmed in living animals or humans.

    Proliferation/anti-apoptosis: PMID 22977872 (Bull Exp Biol Med 2012) — direct test of Lys-Glu-Asp in organotypic neuroimmunoendocrine tissue culture from rats; increased Ki-67, decreased p53. Differentiation markers (related but distinct endpoint, same lab): PMID 22808515 (Bull Exp Biol Med 2012).

  • Antihypoxic protection

    Speculative

    Single 2008 rat study; a related peptide showed the stronger antihypoxic effect.

    PMID 18546825 (Adv Gerontol 2008, Kozina LS) — comparative study of four short peptides in a rat hypobaric hypoxia model, pinealon most effective.

  • Slowing of biological aging markers (geroprophylaxis)

    Speculative

    Single small open-label study with no placebo control; also noted prooxidant effects.

    PMID 26390612 (Adv Gerontol 2015, Meshchaninov VN et al.) — 32 patients (the record lists 18 men and 12 women), Vesugen showed a more visible geroprophylactic effect than Pinealon, with prooxidant activity and reduced CD34+ cells reported in the same study.

  • Pineal gland immune cell proliferation enhancement

    Speculative

    One lab study found enhanced proliferation potential in pineal immune cells, in vitro only.

    PMID 22803057 (Bull Exp Biol Med 2011, Linkova NS et al.) — 'Tripeptide vesugen had no effect on differentiation capacity of immune cells of the pineal gland, but enhanced their proliferation potential.'

Benefits(6)

  • Vascular endothelial cell rejuvenation and Ki-67 restoration

    Khavinson et al. 2014 (Advances in Gerontology, PMID 25051766) — Vesugen stimulated proliferation-associated protein Ki-67 in vascular endothelial cell cultures from old animals. The peptide interacted with the MKI67 gene promoter region, suggesting epigenetic regulation of endothelial proliferation during aging.

  • Improved peripheral vascular blood flow in elderly patients

    Kitachev et al. 2014 (Advances in Gerontology, PMID 25051774) — Despite its lower-limb title, the abstract reports improved penile blood flow in 41 patients with vasculogenic erectile dysfunction. Kitachov et al. 2013 (Advances in Gerontology, PMID 28976154) — Vesugen monotherapy after surgery for chronic lower limb ischemia significantly improved blood flow on both clinical and ultrasonic parameters in 41 patients.

  • Neuroimmunoendocrine cell proliferation and anti-apoptotic effects

    Khavinson et al. 2012 (Bulletin of Experimental Biology and Medicine, PMID 22977872) — Tripeptide Lys-Glu-Asp stimulated proliferation and inhibited apoptosis (decreased p53, increased Ki-67) in organotypic cultures of neuroimmunoendocrine system cells, with more pronounced effects in cultures from old animals.

  • Antihypoxic protection

    Kozina et al. 2008 (Advances in Gerontology, PMID 18546825) — Vesugen demonstrated antihypoxic properties in a model of hypobaric hypoxia, alongside other short peptides (vilon, epitalon, pinealon), suggesting vascular protective effects under oxygen-deprived conditions.

  • Slowing of biological aging markers (geroprophylaxis)

    Meshchaninov et al. 2015 (Advances in Gerontology, PMID 26390612) — In 32 patients aged 41-83 with chronic polymorbidity and organic brain syndrome in remission, Vesugen demonstrated a more visible geroprophylactic effect than Pinealon, with significant anabolic effects and improved CNS activity, slowing the rate of aging by biological age indicators.

  • Pineal gland immune cell proliferation enhancement

    Linkova et al. 2012 (Bulletin of Experimental Biology and Medicine, PMID 22803057) — Vesugen enhanced the proliferation potential of immune cells in the pineal gland in organotypic culture, though it did not affect their differentiation capacity.

Key studies(5)

  1. Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging

    Original research (in vitro)Cell culture study (young and old animal endothelial cells)

    Khavinson VKh, Tarnovskaia SI, Lin'kova NS, Guton EO, Elashkina EV

    Advances in Gerontology (Uspekhi Gerontologii)

    2014

    Vesugen stimulated proliferation-associated protein Ki-67 in vascular endothelial cell cultures from aging animals. Molecular docking showed the peptide interacts with the MKI67 gene promoter region via a CATC sequence located -14 to +12 bp from the transcription start site, suggesting the vasoprotective effect is realized through epigenetic regulation of Ki-67 gene expression.

  2. The role of vasoactive peptide in lower limbs chronic arterial insufficiency treatment

    Clinical study (uncontrolled)41 patientsPost-surgical observation period

    Kitachov KV, Sazonov AD, Kozlov KL, Petrov KYu, Slusarev AS, Sedova EV

    Advances in Gerontology (Uspekhi Gerontologii)

    2013

    Vesugen monotherapy in patients who underwent surgery for chronic lower limb ischemia significantly improved blood flow on both clinical assessment and Doppler ultrasonic parameters. Demonstrated vasoactive peptide efficacy in elderly and senile patients with atherosclerosis-related peripheral arterial disease.

  3. Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells

    Original research (in vitro / organotypic culture)Organotypic cultures from young and old rats3-day culture period

    Chalisova NI, Lopatina NG, Kamishev NG, Linkova NS, Koncevaya EA, Dudkov AV, Kozina LS, Khavinson VKh, Titkov YuS

    Bulletin of Experimental Biology and Medicine

    2012

    Tripeptide Lys-Glu-Asp stimulated proliferation (increased Ki-67) and inhibited apoptosis (decreased p53) in organotypic cultures of neuroimmunoendocrine system cells. Effects were more pronounced in cultures from old animals. The peptide induced expression of CD5 and CD68 markers, primarily affecting nervous and endocrine tissues during aging.

  4. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission

    Clinical study (comparative, uncontrolled)32 participants aged 41–83; the abstract's reported sex counts are internally inconsistent.Treatment course with follow-up

    Meshchaninov VN, Tkachenko EL, Zharkov SV, Gavrilov IV, Katyreva IuE

    Advances in Gerontology (Uspekhi Gerontologii)

    2015

    Vesugen demonstrated a more visible geroprophylactic effect than Pinealon in elderly patients with polymorbidity. Both peptides showed significant anabolic effects and improved CNS activity, slowing the rate of aging by biological age indicators. Prooxidant activity was observed through chemiluminescence.

  5. Peptide Regulation of Gene Expression: A Systematic Review

    Systematic reviewReview of multiple studies

    Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR

    Molecules

    2021

    Comprehensive review demonstrating that short peptides (2-7 amino acids), including KED (Vesugen), can penetrate cell nuclei, interact with nucleosomes, histone proteins, and single/double-stranded DNA. DNA-peptide interactions regulate template-directed reactions, replication, transcription, and DNA reparation. Peptides can regulate DNA methylation status as an epigenetic mechanism for gene activation or repression.

Regulation & availability

Why researchers look at it

Small clinical studies in 41 elderly patients with peripheral vascular disease showed improved blood flow, and in vitro work shows it acts on key aging genes — SIRT1, endothelin-1, and nitric oxide synthase — rather than broadly suppressing symptoms like conventional cardiovascular drugs. No randomized controlled trials or independent Western replication exist. If the vascular gene expression effects were confirmed by rigorous trials, Vesugen could offer a fundamentally different approach to age-related cardiovascular decline.

Estimated cost
$30-80/mo oral capsules
FDA status
Vesugen is not FDA-approved and is not eligible for compounding in the US. No public confirmation of an IND, NDA or BLA submission for Vesugen was identified; FDA generally does not disclose IND existence unless it has previously been publicly disclosed or acknowledged.
WADA status
Not named in the 2026 List. S0 prohibits otherwise-unlisted pharmacological substances lacking governmental approval for human therapeutic use. Supplement marketing does not establish therapeutic approval. Obtain an anti-doping determination before use.
Prescribability
Not prescribable as an FDA-approved medication in the United States or as an EMA-approved drug in Europe. Vesugen has no regulatory approval as a pharmaceutical in any major Western market. In Russia, it is classified and marketed as a biologically active food supplement (BAA — biologicheski aktivnaya dobavka), not as a prescription drug. It is available in Russia in capsule form through supplement channels. There is no legitimate prescription pathway for Vesugen in the United States or EU.
Availability
Vesugen is not available as an approved pharmaceutical product in any major Western market. In Russia it is sold as a biologically active food supplement (BAA) in capsule form, manufactured under the auspices of SPIBG. Oral Vesugen formulations are also marketed as 'lingual' tablets and capsules. Some anti-aging practitioners offer Vesugen as part of peptide bioregulator protocols, but this is outside regulated medical practice.

International status

  • EU

    Not approved

  • US

    Not approved

  • Russia

    Used clinically (Khavinson bioregulator protocol)

  • Worldwide

    Limited to Russian clinical use

Regulatory timeline(11)

  1. 1970s-1980s
    Vladimir Khavinson begins research on organ-specific polypeptide complexes extracted from animal tissues at military medical facilities in the Soviet Union, laying the groundwork for the peptide bioregulator program.
  2. 1992
    Saint Petersburg Institute of Bioregulation and Gerontology (SPIBG) established under Khavinson's direction, becoming the primary center for peptide bioregulator research and development.
  3. 2003-2006
    Vesugen (Lys-Glu-Asp, T-38) synthesized as a short peptide designed to replicate the vasoprotective signaling of natural blood vessel polypeptide complexes. Russian patent filed May 23, 2006 for 'Peptide substance enhancing capillaries resistance' by Khavinson, Grigor'ev, Malinin, and Ryzhak (assignee: OOO SIA Peptaids).
  4. 2008
    First published research on Vesugen: Kozina et al. demonstrate antihypoxic properties of short peptides including Vesugen in hypobaric hypoxia model (PMID 18546825).
  5. 2012
    Multiple in vitro studies published: Khavinson et al. demonstrate Lys-Glu-Asp effects on neuroimmunoendocrine system cells (PMID 22977872) and pineal immune cell proliferation (PMID 22803057).
  6. 2014
    Key mechanistic study published: Khavinson et al. demonstrate epigenetic regulation of Ki-67 in vascular endothelial cells by Vesugen (PMID 25051766). First clinical study on vascular efficacy in elderly patients with chronic arterial insufficiency (PMID 25051774).
  7. 2015
    Meshchaninov et al. publish clinical study showing Vesugen's geroprophylactic effects in 32 elderly patients with polymorbidity (PMID 26390612).
  8. 2013
    Kitachov et al. publish a before-and-after study of Vesugen in 41 patients following surgery for chronic lower-limb ischemia, reporting improved blood-flow measures (PMID 28976154).
  9. 2021
    Khavinson & Popovich publish systematic review 'Peptide Regulation of Gene Expression' in Molecules (PMID 34834147), providing comprehensive mechanistic framework for how short peptides including KED interact with DNA.
  10. 2022
    Khavinson et al. publish research on POT and LAT carrier transport of ultrashort peptides (PMID 35887081), providing mechanistic basis for cellular uptake of Vesugen and similar tripeptides.
  11. 2026-present
    Vesugen remains unapproved by FDA, EMA, or any major Western regulatory agency. Classified as a food supplement (BAA) in Russia. No Western clinical trials have been initiated. No IND applications are publicly known.

Sources & FAQs

Research sources(12)

Frequently asked questions(5)

What is the difference between Vesugen and Ventfort?

Both target vascular function, but they are chemically distinct. Vesugen (Lys-Glu-Asp) is a synthetic tripeptide — a single defined molecule of three amino acids. Ventfort is a natural polypeptide complex extracted from the blood vessels of young cattle, containing a mixture of short peptides. In Khavinson's framework, Vesugen is the synthetic 'cytogen' version designed to replicate the key signaling component found in the natural extract Ventfort. Vesugen offers more precise dosing and molecular characterization, while Ventfort contains a broader but less defined spectrum of peptides.

How does Vesugen enter cells if it is taken orally?

Khavinson's group has published research (PMID 35887081) demonstrating that ultrashort peptides of 2-3 amino acids can be transported into cells via POT (proton-coupled oligopeptide transporter) family carriers, specifically PEPT1 and PEPT2, which transport di- and tripeptides across intestinal and cellular membranes. The LAT1 transporter may also facilitate cellular uptake. However, oral bioavailability of tripeptides is generally low due to enzymatic degradation in the GI tract, and independent pharmacokinetic studies confirming adequate oral absorption of Vesugen have not been published.

Is there clinical evidence that Vesugen works in humans?

Human evidence is very limited. Three small clinical studies have been published, all from Russian research groups. Two vascular reports describe 41 patients each, one on lower-limb ischemia and one whose abstract concerns vasculogenic erectile dysfunction (PMIDs 28976154 and 25051774); participant overlap is unknown. The third examined biological aging markers in 32 patients with polymorbidity (PMID 26390612). These studies reported positive results but lack randomization, blinding, and placebo controls. No Western clinical trials have been conducted, and the results have not been independently replicated.

Can Vesugen be used alongside cardiovascular medications?

No formal drug interaction studies have been conducted. Vesugen's mechanism is epigenetic gene regulation rather than direct pharmacological receptor binding, so classical pharmacokinetic interactions are unlikely. However, if Vesugen produces meaningful blood pressure reduction through improved endothelial function, patients on antihypertensives should monitor blood pressure more frequently during courses and discuss dose adjustments with their physician. Use alongside heart medications (statins, ACE inhibitors, anticoagulants) should be approached cautiously due to the absence of safety data.

Why is most Vesugen research published only in Russian?

Vesugen was developed at a Russian research institute (SPIBG) and the Khavinson peptide bioregulator program is predominantly funded and conducted within Russia. Most studies are published in Russian-language journals such as Advances in Gerontology (Uspekhi Gerontologii) and Bulletin of Experimental Biology and Medicine, which have English abstracts but often lack full English translations. This limits accessibility, peer review by the broader scientific community, and independent replication efforts.